This is a phase 2, single-center study in patients with active cutaneous DM who have had an
inadequate response. An inadequate response is defined as no improvement with standard of
care treatment based on the investigator's opinion.
All subjects will initially receive baricitinib 2mg daily for 8 weeks. If no unexpected
serious adverse events related to baricitinib have occurred during the first 8 weeks of
treatment in the opinion of the investigator, the dose will be increased to 4 mg daily for 16
weeks. Visits are scheduled at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and
24 weeks. Evaluation of primary endpoint occurs at week 24. All subjects receive a phone call
from study